With her company "in the hunt for a series B" that could "unfold in the coming few months," X4 Pharmaceuticals Inc. CEO Paula Ragan told BioWorld that the latest data with X4P-001-IO, a C-X-C receptor type 4 (CXCR4) inhibitor, should give clear-cell renal cell carcinoma cancer patients new hope.